A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery

This is a randomized double-blind placebo-controlled phase II clinical study that included patients with symptoms such as cough, shortness of breath, and fatigue after lung cancer resection surgery. They were given orally modified Bufei Tang granules twice a day for 28 days, with one packet taken orally with water. Using the MDASI-TCM symptom scoring system, evaluate the scores of symptoms such as cough, shortness of breath, and fatigue before and after the experiment, and calculate the difference in scores between the control group and the experimental group before and after the experiment.

Trial Details

NCT ID
NCT06674252
Phase
NA
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Jiawei Bufei Tang granules
  • Placebo
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients with postoperative lung cancer who have clear histological or cytological diagnosis.
  • Age ≥ 65 years old, both male and female are eligible. According to the MDASI-TCM scale evaluation, any of the three symptoms of cough, fatigue, an…
  • The heart function is basically normal; ALT/AST is within 2 times the normal value; SCr is within the normal range.
  • Traditional Chinese medicine syndrome differentiation is characterized by deficiency of both lungs and kidneys.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →